The latest EBIT for 6661.TWO is $-130K as of June 2026. That compares with $5.5M in the prior-year period — down 102.4% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Welgene Biotech ,Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 6661.TWO's EBIT moved from $5.5M to $-130K — a 102.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Welgene Biotech ,Ltd.'s operating scale or balance-sheet position.

Against its sector companies, 6661.TWO currently prints $-130K for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Welgene Biotech ,Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $-130K for 6661.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 6661.TWO's EBIT ($-130K), review year-over-year change from $5.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.